Efficacy and Safety of Hypofractionated Radiotherapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme: A Systematic Review and Meta-Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Nov 5

PMID 31681570

Citations 9

Authors

Guixiang Liao

Zhihong Zhao

Hongli Yang

Xianming Li

Affiliations

Soon will be listed here.

Abstract

Hypofractionated radiotherapy (HFR) is sometimes used in the treatment of glioblastoma multiforme (GBM). The efficacy and safety of HFR is still under investigation. The aim of this systematic review and meta-analysis was to provide a comprehensive summary of the efficacy and safety of HFR, and to compare the efficacy and safety of HFR and conventional fraction radiotherapy (CFR) for the treatment of patients with GBM, based on the results of randomized controlled trials (RCTs). A literature search was conducted to identify Phase II and III trials o comparing the efficacy and safety of HFR and CFR. Study selection, data extraction, and quality assessment, were conducted by two independent researchers. The analysis was performed using RevMan 5.3 and Stata 12.0. Sixteen Phase II and III trials were included in the systematic review, and four RCTs were included in the meta-analysis. Participants treated with HRF and CRF had comparable overall survival (OS) (hazard ratio [HR]: 0.94, 95% confidence interval [CI]: 0.72-1.22, = 0.64) and progression-free survival (PFS) (HR: 1.09, 95% CI: 0.60-1.95, = 0.79), and similar rates of adverse events. However, in participants aged >70 years, those who received HFR had a higher OS than those who received CFR (HR: 0.59, 95% CI: 0.37-0.93, = 0.02). HRF is efficacious and safe for the treatment of GBM. In individuals aged >70 years, treatment with HRF is superior to CFR in terms of OS. The role of HFR in the treatment of GBM in younger individuals and those with good prognostic factors requires further research.

Citing Articles

Trends in the immunotherapy for glioblastoma: A two-decade bibliometric analysis.

Long Z, Yi Z, Yan W, Wang H Hum Vaccin Immunother. 2025; 21(1):2466299.

PMID: 39950580 PMC: 11834472. DOI: 10.1080/21645515.2025.2466299.

Programmed cell death disrupts inflammatory tumor microenvironment (TME) and promotes glioblastoma evolution.

Liang T, Gu L, Kang X, Li J, Song Y, Wang Y Cell Commun Signal. 2024; 22(1):333.

PMID: 38890642 PMC: 11184850. DOI: 10.1186/s12964-024-01602-0.

FLASH Radiotherapy: A FLASHing Idea to Preserve Neurocognitive Function.

Jo H, Oh T, Lee Y, Kang G, Park H, Ahn G Brain Tumor Res Treat. 2023; 11(4):223-231.

PMID: 37953445 PMC: 10641319. DOI: 10.14791/btrt.2023.0026.

The minimal FLASH sparing effect needed to compensate the increase of radiobiological damage due to hypofractionation for late-reacting tissues.

Bohlen T, Germond J, Bourhis J, Bailat C, Bochud F, Moeckli R Med Phys. 2022; 49(12):7672-7682.

PMID: 35933554 PMC: 10087769. DOI: 10.1002/mp.15911.

Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma.

Matsui J, Perlow H, Ritter A, Upadhyay R, Raval R, Thomas E Biomedicines. 2022; 10(7).

PMID: 35885067 PMC: 9313399. DOI: 10.3390/biomedicines10071763.

References

Minniti G, Lanzetta G, Scaringi C, Caporello P, Salvati M, Arcella A . Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2011; 83(1):93-9. DOI: 10.1016/j.ijrobp.2011.06.1992. View

Iuchi T, Hatano K, Kodama T, Sakaida T, Yokoi S, Kawasaki K . Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2014; 88(4):793-800. DOI: 10.1016/j.ijrobp.2013.12.011. View

Roa W, Kepka L, Kumar N, Sinaika V, Matiello J, Lomidze D . International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme. J Clin Oncol. 2015; 33(35):4145-50. DOI: 10.1200/JCO.2015.62.6606. View

Salazar O, Rubin P, Feldstein M, Pizzutiello R . High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys. 1979; 5(10):1733-40. DOI: 10.1016/0360-3016(79)90554-6. View

Ostrom Q, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013. Neuro Oncol. 2017; 18(suppl_5):v1-v75. PMC: 8483569. DOI: 10.1093/neuonc/now207. View

Reddy K, Damek D, Gaspar L, Ney D, Waziri A, Lillehei K . Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012; 84(3):655-60. DOI: 10.1016/j.ijrobp.2012.01.035. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Floyd N, Woo S, Teh B, Prado C, Mai W, Trask T . Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2004; 58(3):721-6. DOI: 10.1016/S0360-3016(03)01623-7. View

Kleinberg L, Slick T, Enger C, Grossman S, Brem H, Wharam Jr M . Short course radiotherapy is an appropriate option for most malignant glioma patients. Int J Radiat Oncol Biol Phys. 1997; 38(1):31-6. DOI: 10.1016/s0360-3016(97)00222-8. View

10.

Budach W, Gioioso D, Taghian A, Stuschke M, Suit H . Repopulation capacity during fractionated irradiation of squamous cell carcinomas and glioblastomas in vitro. Int J Radiat Oncol Biol Phys. 1997; 39(3):743-50. DOI: 10.1016/s0360-3016(97)00362-3. View

11.

Chang E, Yi W, Allen P, Levin V, Sawaya R, Maor M . Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys. 2003; 56(2):519-28. DOI: 10.1016/s0360-3016(02)04522-4. View

12.

Omuro A, Beal K, Gutin P, Karimi S, Correa D, Kaley T . Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clin Cancer Res. 2014; 20(19):5023-31. PMC: 4523080. DOI: 10.1158/1078-0432.CCR-14-0822. View

13.

Lu V, Kerezoudis P, Brown D, Burns T, Quinones-Hinojosa A, Chaichana K . Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis. J Neurooncol. 2019; 143(2):177-185. DOI: 10.1007/s11060-019-03155-6. View

14.

Malmstrom A, Gronberg B, Marosi C, Stupp R, Frappaz D, Schultz H . Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012; 13(9):916-26. DOI: 10.1016/S1470-2045(12)70265-6. View

15.

Minniti G, Amelio D, Amichetti M, Salvati M, Muni R, Bozzao A . Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol. 2010; 97(3):377-81. DOI: 10.1016/j.radonc.2010.08.020. View

16.

Shenouda G, Souhami L, Petrecca K, Owen S, Panet-Raymond V, Guiot M . A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma. Int J Radiat Oncol Biol Phys. 2016; 97(3):487-494. DOI: 10.1016/j.ijrobp.2016.11.006. View

17.

Shah J, Li G, Shaffer J, Azoulay M, Gibbs I, Nagpal S . Stereotactic Radiosurgery and Hypofractionated Radiotherapy for Glioblastoma. Neurosurgery. 2017; 82(1):24-34. DOI: 10.1093/neuros/nyx115. View

18.

Carlson J, Reddy K, Gaspar L, Ney D, Kavanagh B, Damek D . Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. J Neurooncol. 2015; 123(2):251-7. DOI: 10.1007/s11060-015-1791-4. View

19.

Ney D, Carlson J, Damek D, Gaspar L, Kavanagh B, Kleinschmidt-DeMasters B . Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. J Neurooncol. 2014; 122(1):135-43. DOI: 10.1007/s11060-014-1691-z. View

20.

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View